What is the typical onset time for drug‑induced liver injury (DILI) after starting oral fluconazole tablets, and can a single dose cause DILI?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Fluconazole-Induced Liver Injury: Timing and Single-Dose Risk

Fluconazole-induced liver injury typically occurs with prolonged exposure rather than single doses, though rare cases of hyperacute hepatotoxicity have been documented even after minimal exposure. The evidence indicates that DILI risk increases substantially with cumulative drug exposure, particularly beyond 60 defined daily doses (DDDs).

Typical Time Course of Fluconazole DILI

The onset of fluconazole-induced hepatotoxicity is dose-duration dependent:

  • Hepatotoxicity rates: Overall incidence ranges from 1-18% depending on patient population and definition used 1
  • Exposure-dependent risk: The incidence rate of DILI increases dramatically with longer treatment duration, reaching 31.6 per 10,000 persons for fluconazole users overall, but this risk is heavily weighted toward prolonged use 2
  • Cumulative exposure threshold: Risk becomes clinically significant with exposure ≥60 DDDs (approximately 2 months of standard dosing) 2

Pattern of Liver Injury

When fluconazole DILI occurs, it most commonly presents as:

  • Cholestatic pattern (55.2% of cases) 3
  • Asymptomatic transaminase elevations are more common than symptomatic hepatitis 1
  • Discontinuation due to hepatotoxicity is rare (0-5%) in most populations 1

Single-Dose Risk: Rare but Documented

Yes, DILI can occur with single-dose fluconazole, though this is exceptionally rare. A critical case report describes hyperacute liver failure developing shortly after intravenous fluconazole administration in a patient with no prior liver disease 4. This case demonstrated:

  • Acute liver failure (ALF) occurring within days of starting fluconazole
  • Rapid improvement after drug discontinuation
  • Roussel Uclaf Causality Assessment Method score indicating "Highly Probable" DILI
  • Naranjo score confirming "Definite" adverse drug reaction

Important Clinical Context

The single-dose/short-exposure hepatotoxicity appears to be:

  • Idiosyncratic rather than dose-dependent
  • Unpredictable and not related to baseline liver function
  • Potentially fatal: All 6 fatal DILI cases in one large Taiwanese cohort involved fluconazole 2

Risk Factors to Monitor

High-risk populations requiring closer monitoring:

  1. Elderly patients: Old age independently increases risk of fatal fluconazole-induced DILI 2
  2. Immunocompromised patients: Independently associated with 2.67-fold increased hepatotoxicity risk (P = 0.004) 3
  3. Baseline liver enzyme elevation: ALT >16.5 U/L shows modest predictive value (AUC = 0.69) 3
  4. Prolonged treatment courses: Risk escalates significantly beyond 60 DDDs 2

Predictive Model

A combined model incorporating liver enzymes + immune status + comedications achieves superior prediction (AUC = 0.76) compared to liver enzymes alone 3.

Clinical Monitoring Recommendations

For standard short-course therapy (e.g., single 150 mg dose for vaginal candidiasis):

  • Routine liver monitoring is not indicated
  • Counsel patients to report jaundice, dark urine, or severe fatigue
  • Risk is extremely low but not zero

For prolonged therapy (>2 weeks):

  • Baseline liver function tests before initiation
  • Monitor transaminases and bilirubin every 2-4 weeks during treatment 1
  • More frequent monitoring in elderly or immunocompromised patients
  • Discontinue if ALT/AST >5× baseline or bilirubin >3× baseline 1

Critical Pitfalls to Avoid

  1. Don't assume single doses are completely safe: While rare, idiosyncratic reactions can occur even with minimal exposure 4
  2. Don't ignore mild transaminase elevations in high-risk patients: These may herald more severe injury, particularly in the elderly 2
  3. Don't continue fluconazole in the face of significant hepatotoxicity: Unlike some drug reactions, fluconazole hepatotoxicity can progress to ALF 4
  4. Don't overlook the cholestatic pattern: Most fluconazole DILI is cholestatic rather than hepatocellular, which may have a different clinical trajectory 3

The evidence demonstrates that while fluconazole hepatotoxicity is uncommon overall (1-18% depending on definition), it shows clear duration-dependence, with most clinically significant cases occurring after prolonged exposure. However, the documented cases of hyperacute liver failure after minimal exposure underscore that no exposure duration is entirely without risk, particularly in vulnerable populations 2, 4, 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.